Within the newest quarter, 17 analysts offered scores for Crinetics Prescription drugs CRNX, showcasing a mixture of bullish and bearish views.
The desk under supplies a concise overview of current scores by analysts, providing insights into the altering sentiments over the previous 30 days and drawing comparisons with the previous months for a holistic perspective.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Whole Rankings | 8 | 9 | 0 | 0 | 0 |
| Final 30D | 1 | 0 | 0 | 0 | 0 |
| 1M In the past | 2 | 5 | 0 | 0 | 0 |
| 2M In the past | 0 | 0 | 0 | 0 | 0 |
| 3M In the past | 5 | 4 | 0 | 0 | 0 |
Analysts have set 12-month value targets for Crinetics Prescription drugs, revealing a median goal of $64.06, a excessive estimate of $97.00, and a low estimate of $50.00. This present common displays a rise of 18.45% from the earlier common value goal of $54.08.
Understanding Analyst Rankings: A Complete Breakdown
A complete examination of how monetary specialists understand Crinetics Prescription drugs is derived from current analyst actions. The next is an in depth abstract of key analysts, their current evaluations, and changes to scores and value targets.
| Analyst | Analyst Agency | Motion Taken | Ranking | Present Worth Goal | Prior Worth Goal |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Maintains | Purchase | $60.00 | $60.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Purchase | $60.00 | $60.00 |
| Brian Skorney | Baird | Raises | Outperform | $62.00 | $52.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Obese | $70.00 | $50.00 |
| Josh Schimmer | Cantor Fitzgerald | Maintains | Obese | $65.00 | $65.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Purchase | $60.00 | – |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | – |
| Yasmeen Rahimi | Piper Sandler | Raises | Obese | $97.00 | $56.00 |
| Jonathan Wolleben | JMP Securities | Maintains | Market Outperform | $80.00 | – |
| Leland Gershell | Oppenheimer | Raises | Outperform | $55.00 | $54.00 |
| Jonathan Wolleben | JMP Securities | Raises | Market Outperform | $80.00 | $60.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Purchase | $60.00 | $50.00 |
| Lina Kaminski | JonesTrading | Raises | Purchase | $56.00 | $52.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Purchase | $50.00 | – |
| Leland Gershell | Oppenheimer | Raises | Outperform | $54.00 | $48.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Purchase | $50.00 | – |
| Douglas Tsao | HC Wainwright & Co. | Raises | Purchase | $50.00 | $42.00 |
Key Insights:
- Motion Taken: Analysts adapt their suggestions to altering market circumstances and firm efficiency. Whether or not they ‘Preserve’, ‘Increase’ or ‘Decrease’ their stance, it displays their response to current developments associated to Crinetics Prescription drugs. This data supplies a snapshot of how analysts understand the present state of the corporate.
- Ranking: Providing a complete view, analysts assess shares qualitatively, spanning from ‘Outperform’ to ‘Underperform’. These scores convey expectations for the relative efficiency of Crinetics Prescription drugs in comparison with the broader market.
- Worth Targets: Gaining insights, analysts present estimates for the longer term worth of Crinetics Prescription drugs’s inventory. This comparability reveals tendencies in analysts’ expectations over time.
To realize a panoramic view of Crinetics Prescription drugs’s market efficiency, discover these analyst evaluations alongside important monetary indicators. Keep knowledgeable and make considered choices utilizing our Rankings Desk.
Keep updated on Crinetics Prescription drugs analyst scores.
Discovering Crinetics Prescription drugs: A Nearer Look
Crinetics Prescription drugs Inc is a clinical-stage pharmaceutical firm centered on the invention, growth, and commercialization of novel therapeutics for uncommon endocrine ailments and endocrine-related tumors.
Crinetics Prescription drugs’s Monetary Efficiency
Market Capitalization Evaluation: The corporate reveals a decrease market capitalization profile, positioning itself under business averages. This means a smaller scale relative to friends.
Adverse Income Pattern: Inspecting Crinetics Prescription drugs’s financials over 3 months reveals challenges. As of 31 March, 2024, the corporate skilled a decline of roughly -76.11% in income progress, reflecting a lower in top-line earnings. As in comparison with its friends, the income progress lags behind its business friends. The corporate achieved a progress fee decrease than the typical amongst friends in Well being Care sector.
Web Margin: Crinetics Prescription drugs’s internet margin falls under business averages, indicating challenges in reaching sturdy profitability. With a internet margin of -10457.81%, the corporate might face hurdles in efficient price administration.
Return on Fairness (ROE): Crinetics Prescription drugs’s ROE lags behind business averages, suggesting challenges in maximizing returns on fairness capital. With an ROE of -9.47%, the corporate might face hurdles in reaching optimum monetary efficiency.
Return on Belongings (ROA): Crinetics Prescription drugs’s ROA lags behind business averages, suggesting challenges in maximizing returns from its property. With an ROA of -8.3%, the corporate might face hurdles in reaching optimum monetary efficiency.
Debt Administration: With a below-average debt-to-equity ratio of 0.06, Crinetics Prescription drugs adopts a prudent monetary technique, indicating a balanced strategy to debt administration.
Analyst Rankings: Simplified
Analysts are specialists inside banking and monetary programs that usually report for particular shares or inside outlined sectors. These folks analysis firm monetary statements, sit in convention calls and conferences, and converse with related insiders to find out what are often called analyst scores for shares. Sometimes, analysts will fee every inventory as soon as 1 / 4.
Some analysts may even provide forecasts for metrics like progress estimates, earnings, and income to supply additional steering on shares. Traders who use analyst scores ought to be aware that this specialised recommendation comes from people and could also be topic to error.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
